Rosetta Receives NY State Clearance for Second-Gen Test for Cancer of Unknown Primary | GenomeWeb

Rosetta Genomics said this week that the New York State Department of Health has approved the company's miRview Mets 2 microRNA diagnostic, which is used to detect the source of cancers of unknown primary origin.

New York is the only state that requires an independent regulatory review for laboratory-developed tests, Rosetta noted.

With the approval, Rosetta said it can now market the test in all 50 US states.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.